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Aim: We report the physicochemical analysis of nanosystems intended for 
cardiovascular applications and their toxicological characterization in static and 
dynamic cell culture conditions. Methods: Size, polydispersity and ζ-potential were 
determined in 10 nanoparticle systems including liposomes, lipid nanoparticles, 
polymeric and iron oxide nanoparticles. Nanoparticle effects on primary human 
endothelial cell viability were monitored using real-time cell analysis and live-cell 
microscopy in static conditions, and in a flow model of arterial bifurcations. Results & 
conclusions: The majority of tested nanosystems were well tolerated by endothelial 
cells up to the concentration of 100 μg/ml in static, and up to 400 μg/ml in dynamic 
conditions. Pilot experiments in a pig model showed that intravenous administration 
of liposomal nanoparticles did not evoke the hypersensitivity reaction. These findings 
are of importance for future clinical use of nanosystems intended for intravascular 
applications.
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Atherosclerosis and consecutive cardiovascu-
lar events represent one of the biggest global 
health problems [1]. Rupture of vulnerable 
atherosclerotic plaques can lead to ischemia 
of the heart, brain or extremities [2], the pre-
dominant causes of morbidity and mortality 
worldwide. Although both the understand-
ing of disease mechanisms and the imaging 
techniques for atherosclerotic plaque detec-
tion have considerably advanced during the 
last decades, effective approaches to early 
diagnosis and improved targeted therapies 
are still missing [3].
The potential of nanotechnology-based 
therapies to overcome the disadvantages of 
systemic drug administration has been well 
recognized in the field of oncology, but no 
specific nanoparticle-based system has yet 
been approved for diagnosis or therapy of 
cardiovascular diseases. By coating nanopar-
ticles with plaque-specific ligands, signifi-
cantly increased accumulation of these agents 
at the sites of atherosclerotic lesions could 
be achieved, leading to improved detection 
and characterization of the plaques [4]. Fur-
thermore, the treatment outcome can be 
dramatically improved if the drug-carrying 
nanoparticles were directly targeted at the 
diseased artery region, thus reducing the sys-
temic side effects [5]. Hence, our goal is the 
development of effective, safe and innovative 
nanoparticle-based systems for the diagnosis 
and therapy of clinically relevant atheroscle-
rosis. For this purpose, systematic analyses of 
the candidate nanosystems including their 
basic physicochemical characterization, their 
long-term stability and the biological effects 
of nanoparticles, for example, on the vascu-
lar cells, are necessary. So far, the majority 
of studies utilized fibroblasts, mesenchymal 
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stem cells or cancer cells to investigate the biocompat-
ibility of nanosystems. In the recent years, increased 
numbers of publications appeared concerning the 
possible interactions between nanoparticles and endo-
thelial cells, which are the first contact cells in the 
vascular wall for circulating nanoparticles. However, 
these reports usually focus on one type of nanosys-
tems in the context of endothelial viability, or barrier 
function [6–9]. Thus, the purpose of this work was to 
perform comparative physicochemical and biological 
analyses of different types of nanoparticles intended 
for intravascular applications.
The candidate nanosystems included in these analy-
ses comprise lipid nanoparticles, liposomes, polymeric 
nanoparticles, as well as inorganic nanoparticles, that 
are briefly outlined below.
Lipid nanoparticles (Lipidots™) can be considered 
as nano-oil droplets stabilized by a mixture of surfac-
tants (oil-in-water emulsion). They are composed of a 
lipid core, herein a mixture of soybean oil and a wax, 
and a surfactant shell, containing a mixture of phos-
pholipids and polyethylene glycol (PEG)-ylated surfac-
tants [10]. Liposomes are composed of a lipid bilayer 
consisting of amphipathic phospholipids (primarily 
phosphatidylcholine) that enclose an interior aqueous 
space [11]. The head groups of phospholipids are often 
functionalized with polymerizable moieties to improve 
stability (e.g., PEGylated stealth liposomes [12]), or 
with molecular groups, which allow conjugation to 
antibodies or other ligands. Among the advantages 
of lipid nanoparticles and liposomes as drug-delivery 
platforms are the ease of preparation, and the reported 
low immunogenicity [13,14], which is expected to enable 
safe and repeated administration.
Polymeric nanoparticles are composed of polymers, 
most commonly poly(lactic-co-glycolic acid), poly(lactic 
acid), poly(caprolactone), poly(alkylcyanoacrylates) 
or chitosan. The core of the nanoparticles used in 
our studies (∼80% of the total mass) is made of 
poly(isobutylcyanoacrylate) (PIBCA), which is cova-
lently cross-linked with polysaccharides of the coating, 
forming a hydrophilic shell. Functionalization of these 
nanoparticles allows conjugation of targeting ligands, 
for example, fucoidan, a mimic of sialyl Lewis X, the 
natural ligand of P-selectin [15,16], a promising molecule 
to target processes upregulated during destabilization 
of vulnerable plaques. Inorganic nanoparticle systems 
included in this work comprised superparamagnetic 
iron oxide nanoparticles. These particles consist of an 
iron oxide core, which is coated with organic materials 
such as fatty acids, polysaccharides or polymers. Iron 
oxide nanoparticles have good biocompatibility and 
contrast-enhancing properties in MRI, enabling plaque 
detection and characterization [17–20]. Furthermore, 
the magnetic properties of these particles could allow 
their remote targeting by means of external magnetic 
field [21–23].
Although the concept of nanomedicine encom-
passes a localized delivery of nanosystems to the 
diseased organs or target tissues and minimized sys-
temic side effects, the extended circulation time, as 
well as multiple degradation products, may result 
in nanoparticle cytotoxicity [24], or immunogenic-
ity [25]. Hence, in order to predict in vivo responses, 
the toxicity of any nanosystem should first be evalu-
ated on cultured cells (e.g., endothelial cells in the 
case of intravenous application, and the target cells), 
preferably under conditions that resemble the physi-
ological state. Although standard cytotoxicity assays 
have been commonly used to estimate the cellular 
responses to various nanosystems, many nanopar-
ticles interfere with the available photometric assays, 
which may render the experimental results difficult 
to assess and interpret [26]. Here, we compare nano-
systems’ biological effects on primary human endo-
thelial cells, using two complementary methods for 
long-term in vitro monitoring in static conditions 
(real-time cell analysis and live-cell microscopy), as 
well as an in vitro model of arterial bifurcation that 
allows observation of endothelial cells under physi-
ologic-like flow conditions. Furthermore, we report 
the initial results of the pilot studies on the comple-
ment activation-related pseudoallergy (CARPA) 
upon the intravenous administration of liposomal 
 nanoparticles in a pig model.
Materials & methods
In total, ten nanoparticle systems were synthesized and 
investigated, including two types of liposomes (LP-
NPs), three types of lipid nanoparticles (LD-NPs), 
two types of polymeric nanoparticles (PM-NPs) and 
three types of iron oxide nanoparticles (IO-NPs). The 
detailed description of nanoparticle characterization is 
provided in the Online Supplement.
Reagents
Soybean oil and Myrj™ s40 (PEGylated surfactant) 
were purchased from Croda, Chocques, France. Lipoid 
S75 and dipalmitoylphosphatidylcholine were from 
Lipoid GmbH, Ludwigshafen, Germany. Suppocire 
NB was from Gatefosse, Saint-Priest, France. 1-palmi-
toyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 
cholesterol, 1,2-distearoyl-sn-glycero-3-phospho-eth-
anolamine-N-[methoxy (polyethylene glycol)-2000] 
(DSPE-PEG-2000) and 1,2-distearoyl-phosphatidyl-
ethanolamine-methyl-polyethyleneglycol conjugate-550 
(DSPE-PEG550) were purchased from Avanti Polar 
Lipids, Inc. (AL, USA).
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Dextran T70 was from Roth (Karlsruhe, Germany), 
or from Amersham Pharmacia Biotech (Freiburg, Ger-
many), and dextran T40 from PharmaCosmos (Hol-
baek, Denmark). Carboxymethyl-dextran sodium salt 
(CM-Dextran) was purchased from Sigma Aldrich 
(Saint Quentin Fallavier, France) and diethylamino-
ethyl-dextran 20 (DEAE-dextran) from TdB Consul-
tancy (Uppsala, Sweden). Low molecular weight Fucoi-
dan (3–8 kDa, Fucoidan Ascophyscient®) was from 
Algues et Mer (Ouessant, France). IBCA (isobutylcya-
noacrylate, Glue 368) was from Orapi (Saint-Vulbas, 
France). Bovine serum albumin (BSA) and iron (II) 
chloride tetrahydrate were from Merck, Darmstadt, 
Germany. Lauric acid, epichlorohydrin and dextranT6 
(Mw = 6 kDa) were from Sigma Aldrich, Munich, Ger-
many. Ceric (IV) ammonium nitrate and tri-sodium 
citrate dihydrate were purchased from Fluka (Saint 
Quentin Fallavier, France). NaOH, HCl (25%), NH
3
 
(25%) and nitric acid (65%w/w) were from Roth. Iron 
(III) chloride hexahydrate was purchased from Sigma-
Aldrich or from Roth. All compounds used were of 
pharmaceutical (Ph. Eur) or highly pure (≥99%) grade 
and were used without any further purification.
Nanoparticle synthesis
Lipidots
Lipid nanoparticles (LD-NP) were prepared by the 
sonication method [10]. Briefly, the lipid phase was 
prepared by mixing Suppocire™ NB, soybean oil and 
lipoid S75. The aqueous phase, containing Myrj s40 
(PEGylated surfactant) in phosphate buffered saline 
(PBS), was heated to 50°C to melt the surfactant and 
then mixed with the lipid phase. Following sonica-
tion for 5 min, the samples were dialyzed against PBS 
and sterilized by filtration through a 0.22 μm filter. 
The batches of particles with specified diameter were 
obtained by altering the lipid and surfactants ratios. 
Three different sizes (diameters) were formulated: 
50 nm (LD-NP1), 80 nm (LD-NP2) and 120 nm 
(LD-NP3).
Liposomes
For the synthesis of sterically stabilized PEGylated 
liposomes (LP-NP1), POPC, cholesterol (Avanti Polar 
Lipids) and DSPE-PEG-2000 were used. Lipids were 
dissolved in chloroform-methanol 2:1 (v/v) at molar 
ratios of 3:2:0.15. LP-NP1 were made using a dry 
film rehydration technique, followed by size extru-
sion, as described previously [12,27]. Briefly, the organic 
solvent was evaporated under a stream of nitrogen to 
obtain a lipid film. For complete removal of solvents 
the film was dried in a vacuum chamber overnight. 
Subsequently, the dry lipid film was hydrated in PBS 
and size-extruded using an Avanti Polar mini-extruder 
(Avanti Polar Lipids, Inc.) and 100 nm polycarbonate 
membranes.
The LP-NP2 liposomes were prepared using the lipid 
injection method, by mixing the ethanolic lipid solu-
tion with the aqueous phase under magnetic stirring at 
60°C. Briefly, dipalmitoylphosphatidylcholine, choles-
terol (BUFA, Uitgeest, The Netherlands), and DSPE-
PEG550 were dispersed in ethanol at molar ratios of 
1.85:1:0.15. Subsequently, the lipid solution was trans-
ferred into PBS previously heated to 60°C. The result-
ing emulsion was downsized by multiple extrusion 
steps through polycarbonate filter membranes with 
decreasing pore sizes of (200–100 nm). Subsequently, 
ethanol and dissolved lipids were removed by dialysis 
against PBS.
Polymeric nanoparticles
Polymeric nanoparticles (PM-NP) were synthesized 
by a redox radical emulsion polymerization method. 
This method ensures the polysaccharides of the shell to 
assemble into a brush-like layer of coating. Here, two 
different coatings were used: 90% CM-Dextran/10% 
Fucoidan (PM-NP1); and 80% DextranT70 (Phar-
macia Biotech)/10% DEAE-dextran/10% Fucoidan 
(PM-NP2). Briefly, polysaccharides (0.1375 g) were 
dissolved in a nitric acid solution (2 × 10–1 M) at 40°C 
and left under nitrogen bubbling for 10 min. Polymer-
ization was initiated by adding 2 ml ceric (IV) ammo-
nium nitrate solution (8 × 10–2 M) in nitric acid and 
0.5 ml of IBCA monomers to the polysaccharide solu-
tion under nitrogen atmosphere and vigorous stirring. 
The reaction was then left for 40 min at 40°C under 
gentle stirring, followed by cooling to room tempera-
ture. Subsequently, 1.25 ml of a trisodium citrate dihy-
drate solution (1.02 M) was added to the suspension 
and the pH was adjusted to 7.0 with NaOH. PM-NPs 
were purified by dialysis (molecular weight cut-off 100 
kDa) against water. One final dialysis was performed 
against NaCl 0.9%. Nanoparticles were sterilized by 
filtration through a 0.45 μm filter, followed by 15 min 
exposure to UV radiation.
Iron oxide nanoparticles (IO-NP)
Lauric acid/BSA-coated magnetite nanoparticles (IO-
NP1) were synthesized by coprecipitation, subsequent 
in situ coating with lauric acid and formation of an 
artificial albumin corona as previously described [28]. 
Briefly, Fe (II) and Fe (III) salts at a defined molar ratio 
(Fe3+/Fe2+ = 2) were dissolved in 20 ml of water and 
stirred at 80°C under argon atmosphere, followed by 
addition of 20 ml of NH
3
 solution (25%). The solution 
was heated to 90°C and 1.25 g lauric acid, dissolved 
in acetone, was added. The brownish suspension was 
left to homogenate for 30 min at 90°C. The suspen-
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sion was then dialyzed multiple times against water. 
Subsequently, IO-NP1 were stabilized by incubation 
with a freshly prepared 20% BSA solution, purified 
by centrifugal ultrafiltration (molecular weight cut-
off 100 kDa), and sterilized by filtration through a 
0.22 μm filter.
For preparation of dextran-coated magnetite 
nanoparticles (IO-NP2), the synthesis method by 
Unterweger et al. was used [29]. Briefly, Fe (II) and 
Fe (III) salts in molar ratios (Fe3+/Fe2+ = 2) as well as 
1.75 g of dextranT6 were dissolved in water. After cool-
ing to 4°C under continuous stirring and argon atmo-
sphere, 5 ml of ice-cold 25% NH
3
 was added. After 5 
min, the reaction mixture was heated and kept at 75°C 
for a further 40 min, followed by cooling to RT and 
dialysis (molecular weight cut-off 8 kDa). The mix-
ture was then cleared from excess dextran and concen-
trated to a total volume of 20 ml using ultrafiltration 
(molecular weight cut-off 100 kDa). To stabilize the 
dextran coating, crosslinking was performed by add-
ing 4 ml of epichlorohydrine dropwise to the nanopar-
ticle suspension after alkalization with NaOH under 
vigorous stirring for 24 h. The solution was then dia-
lyzed against water, concentrated by ultrafiltration and 
sterile  filtered through 0.22 μm membrane.
IO-NP3 nanoparticles were also synthesized by the 
coprecipitation method. Briefly, Fe (II) and Fe (III) 
salts at a defined molar ratio (Fe3+/Fe2+ = 2) were dis-
solved in water under nitrogen atmosphere, followed 
by addition of a preheated strong alkali solution under 
continuous stirring. In the second step, the coating 
material (carboxydextran) was added to the aque-
ous suspension of iron oxide nanoparticles followed 
by heating under reflux. After cooling, the resulting 
material was filtered and dispersed in water, followed 
by dialysis against water, and sterile filtration using a 
0.45 μm filter.
Physicochemical characterization & stability on 
storage
Z-averaged hydrodynamic diameter, polydispersity 
(PDI) and ζ-potential were determined with a Zeta-
sizer Nano ZS (Malvern) using standard polysty-
rene cuvettes and disposable folded capillary cells 
(DTS1070), respectively. All samples were diluted 
prior to the measurement according to the produc-
ers’ instructions: LD-NPs, LP-NP1 suspensions were 
diluted 10× in deionized and 0.2 μm-membrane fil-
tered water, LP-NP2 were diluted 10× in PBS pH 7.4, 
and PM-NPs and IO-NPs were diluted between 50× 
and 100× in ultrapure water. Samples were equilibrated 
to 25°C and 3 × > 10 runs of 10 s performed in 173° 
backscatter mode. The employed refractive indices 
and absorption coefficients for the different particles 
systems were: LD-NPs, 1.5, 0.1; LP-NP1, 1.4, 0.001; 
LP-NP2, PM-NPs, 1.59, 0.01; IO-NPs, 2.9, 5.18. To 
determine sample stability, the first time-point for 
physicochemical characterization was set at 1 month 
post synthesis date, followed by the subsequent mea-
surements after 3 and 6 months of storage at 4°C. The 
detailed description of further characterization meth-
ods relevant for the respective nanoparticle types is 
provided in the Online Supplement.
Real-time cell analysis
Human umbilical vein endothelial cells (HUVECs) 
were isolated from freshly collected umbilical cords 
(kindly provided by the Department of Gynaecol-
ogy, University Hospital Erlangen) and cultured as 
described in the Online Supplement. In all experiments, 
HUVECs at passage 1–2 were used. The use of human 
material was approved by the local ethics committee 
at the University Hospital Erlangen (review number 
237_12B from 19.09.2012). For monitoring the effects 
of nanoparticles on HUVEC viability, the xCELLi-
gence system (RTCA DP Analyzer, Roche Diagnostics, 
Mannheim, Germany) was used [30]. Experiments were 
performed in 16-well E-plates (ACEA Bioscience, CA, 
USA), in which the impedance is measured with the 
help of microelectrodes localized at the bottom of the 
wells (for detailed description, see Online Supplement).
For the background measurement, 100 μl of cell-
free endothelial cell growth medium was added to 
the wells. Afterwards, 50 μl of media from each well 
were replaced with 50 μl of cell suspension containing 
1 × 103 HUVECs. About 30 min after seeding of the 
cells, monitoring of impedance by the xCELLigence 
system was initiated. At 24 h after seeding, an addi-
tional 100 μl of media containing different concen-
trations of nanoparticles were added to the wells, as 
follows: (a) for controls, 100 μl of pure medium with-
out nanoparticles, and (b) for the treatment samples, 
100 μl of medium containing nanoparticles at concen-
trations 2× higher than the required final nanoparticle 
concentration. The final nanoparticle concentrations 
were as follows: 0, 12.5, 25, 50, 100, 200 and 400 μg/
ml. Concentrations for iron oxide nanoparticles were 
calculated as total iron (Fe) concentration. The con-
centrations for lipid nanoparticles, liposomes and poly-
meric nanoparticles were calculated as total dry mass 
weight per volume. Cell growth was monitored every 
10 min for 96 h. The experiments were performed in 
hexaplicate.
Live-cell microscopy
HUVECs were seeded in 96-well plates at 2 × 103 
cells/well in 100 μl medium. At 24 h after seeding, 
additional 100 μl of media containing different con-
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centrations of nanoparticles were added to the wells, 
as described in detail above. Cell growth was moni-
tored for 72 h using a live cell-imager (IncuCyte FLR 
microscope system, Essen Bioscience, MI, USA). The 
experiments were performed in hexaplicate.
Flow experiments
Flow experiments were performed as previously 
described (see [31] and Online Supplement). For the 
perfusion with nanoparticles, two different concen-
trations were used (100 μg/ml and 400 μg/ml). Sub-
sequently, HUVECs were stained with Alexa488-
phalloidin (PromoKine, Heidelberg, Germany). Cell 
nuclei were counterstained with DAPI (Molecular 
Probes, Darmstadt, Germany). Images were obtained 
using fluorescence microscope Zeiss Axio Observer. Z1 
(Carl Zeiss AG, Oberkochen, Germany). The conflu-
ence was determined on ×10 objective magnification 
images using ImageJ software.
Pig model of complement activation-related 
pseudoallergy (CARPA)
Pilot studies in a pig model of infusion reaction to 
LP-NP1 were performed as described by Szebeni [32]. 
Briefly, domestic male Yorkshire pigs (20–25 kg) were 
anesthetized with isoflurane (2–3% in O
2
). Intubation 
was performed with endotracheal tubes to maintain 
free airways. Oxygen saturation was monitored using a 
pulse-oximeter fixed on the tail, and body temperature 
was monitored rectally. A capnograph was connected 
to the tracheal tube to monitor EtCO
2
 and the respi-
ratory rate (CAP10, Medlab GmbH, Karlsruhe, Ger-
many). To measure the pulmonary arterial blood pres-
sure (PAP), a Swan-Ganz catheter (AI-07124, 5 Fr. 110 
cm, Arrow International, Inc., Teleflex, Athlone, Ire-
land) was introduced into the pulmonary artery via the 
right external jugular vein – right atrium – right ven-
tricle, while systemic arterial blood pressure (SAP) was 
measured in the femoral artery. LP-NP1 and zymosan 
were injected in the animals in bolus (<10 s) via the 
left external jugular vein. The amount of test mate-
rial injected is given as mg phospholipids/kg, unless 
otherwise indicated. Hemodynamic changes were con-
tinuously monitored at 1000 Hz sampling rate, using 
an AD Instruments PowerLab System with LabChart 
Pro v6 software. From the mean PAP, SAP and heart 
rate (HR) data about 20 s intervals were averaged 
and evaluated by AD Instruments LabChart Pro v6 
software modules. The usual evaluated periods were: 
before the test material injection, then 20 s in every 
minute for 10 min, and every 5 min until the end of 
the reaction. Plasma levels of thromboxane B2 (TXB2, 
the stable metabolite of TXA2) were measured with 
a commercially available ELISA kit (Cayman Chemi-
cals, MI, USA). The study was approved by the local 
ethics committee for animal experimentation.
Statistical analyses
The differences between the in vitro treatment groups 
were calculated using ANOVA on Ranks. Data were 
expressed as mean ± SEM, unless stated otherwise. 
In vivo changes in SAP and HR, as well as TXB2 were 
compared with time 0 (baseline) values using one-way 
ANOVA with Dunnett’s post hoc test. p < 0.05 was 
considered statistically significant.
Results
Nanoparticle characterization & stability on 
storage
The detailed description of physicochemical prop-
erties of respective nanoparticles is provided in the 
Online Supplement (Supplementary Figures 1–16, see 
also [10,12,27–29]). To validate the stability of physi-
cochemical parameters upon prolonged storage, the 
Z-averaged hydrodynamic diameter, the polydisper-
sity (expressed as polydispersity index, PDI) and the 
ζ-potential of the investigated nanoparticles were 
determined at different time points. The first collective 
analysis time-point was set at 1-month post synthesis 
date. The detailed characteristics of the nanoparticles 
are shown in Table 1. To ensure the long-term particle 
stability, subsequent measurements were performed on 
the various nanoparticles after 3 and 6 months of stor-
age at 4°C in their respective dilution media. As shown 
in Table 2, no significant changes in hydrodynamic 
diameter, PDI and ζ-potential of the nanoparticles 
were found, indicating a good stability with time.
Real-time cell analysis of nanoparticle 
cytotoxicity
Endothelial cells are the first-contact vascular cells 
for any nanosystems designed for intravascular appli-
cations. A suitable in vitro method to investigate the 
potential toxicity of intravenously applied nanosystems 
is to test their effect on HUVECs, which serve as a 
model system of the human endothelium. Real-time 
cell analysis using xCELLigence is a well-established 
method used, among others, for nanotoxicity stud-
ies [33]. As described in detail in Online Supplement, 
cell index measured with this technique reflects cell 
viability, number, morphology and adhesion strength. 
To ensure that the tested nanoparticles do not inter-
fere with the impedance measurements, a series of 
control experiments was performed. Importantly, the 
presence of nanoparticles alone (without cells) did not 
affect the impedance measured by the electrodes, as 
shown in Supplementary Figures 17–20. In studies with 
HUVECs, a steady increase in cell index was observed 
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over time in control (untreated) endothelial cells, but 
also in the cells treated with LP-NPs up to the highest 
tested concentration (400 μg/ml, Figure 1). There were 
no significant differences in the growth curves of the 
liposome-treated cells versus control samples, show-
ing a similar increase of cell index until the end of the 
measurement at 72 h post-application. In cells treated 
with 100 μg/ml LD-NP1 (Figure 2A), a decrease in 
cell index at 48 and 72 h was observed in comparison 
to control, indicative of cell growth inhibition or loss 
of adherence. Interestingly, the decrease in cell indi-
ces became obvious at the concentration of 100 μg/
ml for LD-NP1, 200 μg/ml for LD-NP2 and above 
200 μg/ml for LD-NP3, suggesting that the larger 
lipid nanoparticles may be better tolerated by endo-
thelial cells (Figure 2). For polymeric nanoparticles 
(Figure 3), the decrease in endothelial cell index rela-
tive to the preapplication values, which was indicative 
of cytostatic or cytotoxic effects, was induced from the 
concentration of 50 μg/ml for PM-NP1, and from 100 
μg/ml for PM-NP2.
In cells treated with 50 μg/ml IO-NP1 (Figure 4), a 
significantly lower cell-index in comparison to control 
was observed at 48 and 72 h, indicative of cell growth 
inhibition. The decrease in endothelial cell index rela-
tive to preapplication values, indicative of negative 
effects on cell viability or adherence was induced from 
the concentration of 100 μg/ml IO-NP1 (Figure 4A). 
There were no significant differences in the growth 
curves of the cells treated with IO-NP2 versus control 
samples, showing a similar increase of cell index until 
the end of the measurement at 72 h post-application 
(Figure 4B). Since IO-NP3 were no longer stable upon 
dilution in the serum-containing endothelial cell 
Table 1. Physicochemical characterization of nanoparticles.
Nanoparticle type Z-avg d(nm) PDI ζ (mV) SD ζ (mV)
LD-NP1 53.3 0.156 - 7.0 14.5
LD-NP2 82.8 0.191 - 9.0 14.6
LD-NP3 120.1 0.151 - 8.8 8.4
LP-NP1 138.6 0.104 - 16.3 7.4
LP-NP2 108.8 0.034 -9.0 4.7
PM-NP1 145.1 0.072 - 51.0 5.6
PM-NP2 226.9 0.194 3.3 5.7
IO-NP1 78.7 0.145 - 37.3 12.9
IO-NP2 79.6 0.173 13.7 9.3
IO-NP3 57.5 0.217 - 24.9 8.4
Physicochemical characterizations were performed for various nanosystems 1 month after particle synthesis. Z-avg d: Z-averaged 
hydrodynamic diameter; PDI: Polydispersity (PDI = SD2/d2); ζ: Zeta-potential; SD ζ: Standard deviation of zeta-potential; NP: Nanoparticles; 
LD: Lipidots; LP: Liposomes; PM: Polymeric NPs; IO: Superparamagnetic iron oxide nanoparticles.
Table 2. Nanoparticle stability on storage.













PDI ζ (mV) SD ζ 
(mV)
LD-NP1 53.3 0.156 -7.0 14.5 52.5 0.142 -8.5 11.5 53.3 0.193 -7.7 4.6
LD-NP2 82.8 0.191 -9.0 14.6 83.0 0.173 -8.6 6.9 84.3 0.213 -8.2 5.9
LD-NP3 120.1 0.151 -8.8 8.4 125.7 0.161 -9.0 7.3 123.5 0.156 -8.4 5.3
LP-NP1 138.6 0.104 -16.3 7.4 143.2 0.110 -10.7 8.7 165.5 0.199 -11.5 7.4
LP-NP2 108.8 0.034 -9.0 4.7 108.6 0.016 -7.4 9.7 107.6 0.040 *  
PM-NP1 145.1 0.072 -51.0 5.6 135.7 0.087 -53.4 8.4 139.1 0.108 -47.6 10.1
PM-NP2 226.9 0.194 3.3 5.7 237.5 0.235 9.4 5.7 215.2 0.126 11.4 5.6
IO-NP1 78.7 0.145 -37.3 12.9 84.4 0.258 -44.3 11.6 71.1 0.160 -43.4 10.7
IO-NP2 79.6 0.173 13.7 9.3 80.6 0.150 -17.0 11.1 81.1 0.140 -0.65 6.6
IO-NP3 57.5 0.217 -24.9 8.4 68.9 0.252 -35.0 9.6 58.8 0.228 -26.6 7.2
Physicochemical parameters were obtained for the various nanosystems at 1, 3 and 6 months after particle synthesis. Z-avg d: Z-averaged hydrodynamic diameter; 
PDI: Polydispersity (PDI = SD2/d2); ζ: Zeta-potential; SD ζ: Standard deviation of zeta-potential; NP: Nanoparticles; LD: Lipidots; LP: Liposomes; PM: Polymeric NPs; 
IO: Superparamagnetic iron oxide nanoparticles. * No steady values could be obtained due to foaming during measurement.
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medium, yielding significant nanoparticle agglomera-
tion at concentrations above 50 μg/ml, the effect of 
IO-NP3 on HUVECs could not be investigated.
Live cell imaging of nanoparticle-treated 
endothelial cells
The results of real-time cell analysis were validated 
using live-cell microscopy. In contrast to real-time cell 
analysis, which estimates cell numbers, attachment 
and viability based on the impedance measurements, 
live-cell microscopy allows the observation of cell 
morphology, and the measurement of confluence at 
the same time (see also Supplementary Figures 21–24). 
Using this method, no differences were observed in 
confluence (Supplementary Figure 21) or morphol-
ogy between untreated cells and the cells treated with 
different concentrations of LP-NPs, confirming the 
real-time analysis data (Figure 1A–C). Upon treatment 
with LD-NP1, endothelial cell numbers were only 
slightly affected at 100 μg/ml, but the morphology of 
the cells changed, starting at around 24 h of incuba-
tion, leading to an elongated phenotype at 28 h post-
application. At 200 μg/ml, stronger cell elongation, 
and reduced number of adherent cells were observed 
at 24 h (Figure 2A, Supplementary Figure 22). For 
LD-NP2, slight morphological changes became appar-
ent at 100 μg/ml after 30 h of incubation, which were 
more strongly pronounced at 200 μg/ml, in parallel 
with reduced cell numbers after 48 h of incubation 
(Figure 2B). In LD-NP3-treated cells, reduced prolifer-
ation and strong elongation were detectable at 100 μg/
ml after 72 h and at 200 μg/ml after 48 h incubation 
(Figure 2C). Cytotoxicity was apparent for LD-NP2 at 
400 μg/ml after 24 h incubation, for LD-NP3 at 400 
μg/ml after 48 h of incubation and for the smallest 
LD-NP1 at 200 μg/ml after 24 h of incubation.
Upon treatment with PM-NP1, strong reduction 
in cell number (reflected by decreased confluence, see 
Supplementary Figure 23) was visible at 50 μg/ml, 
whereas the presence of dead cells was observed at 100 
μg/ml (Figure 3A). Treatment with 50 μg/ml PM-NP2 
did not significantly affect cell numbers or morphol-
ogy. Cytotoxic effects were observable from 100 μg/
ml (Figure 3B). In the case of iron oxide nanoparticles, 
decreased cell numbers were observed upon treatment 
with 100 μg/ml IO-NP1, and a strong growth inhibi-
tion accompanied by cell shape change was induced 
at 200 μg/ml (Figure 4A, Supplementary Figure 24). 
In contrast, up to 400 μg/ml of IO-NP2 were well 
tolerated by endothelial cells and did not affect the 
morphology or confluence of cells as compared with 
untreated controls (Figure 4B).
Taken together, the results of real-time cell analysis 
and live-cell microscopy indicated that for the major-
ity of the tested nanosystems, there were no signifi-
cant toxic effects on HUVECs up to the concentra-
tion of 100 μg/ml. Because of the biological/cytotoxic 
effects observed at and above 100 μg/ml for LD-NPs, 
PM-NPs and IO-NPs, subsequent studies under flow 
conditions were performed to investigate the effects 
of circulating nanosystems in physiological-like 
 settings.
Nanoparticle effects on ECs in dynamic cell 
culture conditions
In physiological conditions, endothelial cells are con-
stantly exposed to shear stress induced by the flow of 
blood and its viscosity, and their responses to stimuli 
are determined by the patterns of shear stress. Whereas 
laminar flow protects endothelial cells from harmful 
stimuli, nonuniform shear stress induces endothelial 
activation [31]. Furthermore, recent studies showed 
that the endothelial uptake on untargeted nanoparti-
cles greatly depends on the presence and magnitude of 
shear stress [34–36]. Therefore, experiments under flow 
conditions are necessary to estimate the cell responses 
in physiological-like settings. In vitro, the toxic effects 
of circulating substances manifest themselves as endo-
thelial cell shrinking and detachment. Consequently, 
the viability and confluence of the cells upon treatment 
with nanoparticles, as well as their morphology and 
cell–cell contacts can be assessed by immunofluores-
cent staining. We therefore perfused a HUVEC mono-
layer with medium containing 100 or 400 μg/ml of 
nanoparticles for 18 h and subsequently compared the 
nanoparticle effects on cells exposed to different types 
of shear stress (laminar vs non-uniform shear stress). 
In contrast to static conditions, all LD-NPs (Figure 5) 
and IO-NP1 (Figure 6) were well tolerated by the cells 
up to 400 μg/ml and did not affect endothelial cell 
viability and morphology, nor induced cell detachment 
due to shear stress exposure. In the case of PM-NP1, 
the circulating nanoparticles induced endothelial cell 
rounding at 100 μg/ml, and resulted in massive cell 
detachment both in the laminar and nonuniform shear 
stress region at 400 μg/ml (Figure 6A). The negative 
effects of circulating PM-NP2 on HUVECs remained 
observable at 100 μg/ml (Figure 6B), similar as seen in 
static conditions.
Reaction to liposomal nanoparticles in a pig 
model of CARPA
Evaluation of cardiovascular changes upon intra-
venous bolus injection of LP-NP1 at two different 
doses (0.1 and 0.5 mg phospholipid/kg) was done in 
domestic pigs. After the negative control injection (5 
ml saline), the first test dose (0.1 mg phospholipid/kg) 
was diluted in 5 ml of sterile PBS and injected as a 
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Figure 1. Biological effects of liposomes on endothelial cells grown in static conditions. HUVECs were treated with (A) LP-NP1 and (B) 
LP-NP2 for up to 72 h. Left panel: Real-time cell analysis. Cell index is displayed as x-fold of untreated controls. Right panel: Live-cell 
microscopy images at ×10 objective magnification. Data are expressed as mean ± SEM.  
*p < 0.05, **p < 0.01, ***p < 0.001 vs control (one-way ANOVA); n = 4.
Figure 2. See facing page. Biological effects of lipid nanoparticles on endothelial cells grown in static conditions. HUVECs were 
treated with (A) LD-NP1, (B) LD-NP2 and (C) LD-NP3 for up to 72 h. Left panel: Real-time cell analysis. Cell index is displayed as x-fold 
of untreated controls. Right panel: Live-cell microscopy images at ×10 objective magnification. Data are expressed as mean ± SEM.  
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bolus in the external jugular vein of anesthetized ani-
mal (see online supplement for the outline of the pig 
model). The saline injection caused no cardiovascular 
changes. Following the injection of LP-NP1 at 0.1 mg/
kg dose, mild PAP increase was observed (from 16.6 to 
20.9 mmHg), without any other changes (Figure 7A). 
The steady increase of HR was not nanoparticle-related. 
To test for the presence of tachyphylaxis (desensitiza-
tion), the same dose was repeatedly injected 30 min 
later. This repeated 0.1 mg/kg bolus injection caused 
no reaction, just like the subsequent injection of 5× 
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Figure 3. Biological effects of polymeric nanoparticles on endothelial cells grown in static conditions. HUVECs were treated with (A) 
PM-NP1 and (B) PM-NP2 for up to 72 h. Left panel: Real-time cell analysis. Cell index is displayed as x-fold of untreated controls. Right 
panel: Live-cell microscopy images at ×10 objective magnification. Data are expressed as mean ± SEM.  
*p < 0.05, **p < 0.01, ***p < 0.001 vs control (one-way ANOVA); n = 5 for PM-NP1; n = 3 for PM-NP2.
PM-NP1
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was full tachyphylaxis. The positive control, zymosan 
at 0.1 mg/kg evoked severe PAP increase and a short 
lasting SAP decrease. The most characteristic PAP 
changes during the three LP-NP1 and zymosan injec-
tions, expressed as the % of the preinjection values, are 
shown in Figure 7B.
Pulmonary hypertension is closely associated with 
elevations of plasma thromboxane in response to zymo-
san-induced complement activation [37,38]. TXB2 mea-
surement in blood samples collected before injections 
and during the reactions showed an approximate 40% 
TXB2 elevation in the later phase (10 min) following 
the first 0.1 mg/kg LP-NP1 injection (Figure 7C). Upon 
repeated injection, the same dose caused neither PAP 
nor TXB2 elevation (not shown), which confirmed the 
presence of tachyphylaxis.
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Figure 4. Biological effects of iron oxide nanoparticles on endothelial cells grown in static conditions. HUVECs were treated with (A) 
IO-NP1 and (B) IO-NP2 for up to 72 h. Left panel: Real-time cell analysis. Cell index is displayed as x-fold of untreated controls. Right 
panel: Live-cell microscopy images at ×10 objective magnification. Data are expressed as mean ± SEM.  
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Discussion
Detailed in vitro characterization facilitates the predic-
tion of nanoparticle behavior in more complex physi-
ological conditions, and is a prerequisite for human 
use [39]. We therefore investigated 10 nano particle 
systems, including lipid nanoparticles (Lipidots), 
liposomes, polymeric nanoparticles and iron oxide 
nanoparticles with regard to their physicochemical 
features, stability and biological effects. Important 
parameters affecting nanoparticle properties include 
size, charge and PDI [40]. Size is one of the critical fac-
tors that affect the circulation time and bioavailabil-
ity of nanoparticles. Surface charge, indicated by the 
ζ-potential, has a strong influence on nanoparticle sta-
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Figure 5. See facing page. Biological effects of circulating lipid nanoparticles on endothelial cells grown under flow conditions. 
HUVECs were grown in bifurcating slides until confluence and perfused for 18 h with medium containing LD-NP1 (A), LD-NP2 (B), or 
LD-NP3 (C) at 100 and 400 μg/ml. Left panel: Fluorescent images of representative laminar and nonuniform regions at 20× objective 
magnification are shown. F-actin was visualized with Alexa 488-conjugated 488 (green) and nucleus with Hoechst 33342 (blue). Right 
panel: The graphs show a semiquantitative analysis of the confluence in laminar (green bars) and nonuniform region (red bars), 
determined on ×10 objective magnification images using ImageJ software. Nanoparticle-untreated controls (white columns) were set 
to 100%. Data are expressed as mean ± SEM.  
*p < 0.05, **p < 0.01, ***p < 0.001 vs corresponding control.
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bility in biological fluids. Moreover, positively charged 
nanoparticles enhance cellular uptake and can induce 
cytotoxicity [40,41]. Nanoparticles with a ζ-potential 
above (+/-) 30 mV are usually considered as colloidally 
stable, since the surface charge prevents their aggrega-
tion, but ζ-potential cannot be regarded as an absolute 
predictor of nanoparticle stability, especially in bio-
logical fluids as the ζ-potential is dependent on solvent 
composition. Steric repulsion, such as the hindrance 
provided by a PEGylated coating of the nanoparticle 
surface, can also provide high colloidal stability despite 
a nearly neutral ζ-potential [42].
Nanoparticle agglomeration is thus influenced by 
their physicochemical properties, but also by extrin-
sic factors, for example, temperature, as well as pH, 
osmotic strength and the presence of serum in the 
dispersion media. For clinical applications, nanopar-
ticle agglomeration may be a key factor limiting their 
use in patients, as it affects bioavailability, and thus 
efficacy. Aggregated nanoparticles are no longer nano-
sized, and undergo a rapid recognition by the reticulo-
endothelial system followed by the clearance via liver 
or spleen. Moreover, the presence of agglomerates in 
circulation may cause serious undesirable side effects, 
such as clogging blood or lymphatic vessels [41]. In 
our study, although the results of physicochemical 
characterization of all investigated nanosystems in 
their respective dilution media indicated a good col-
loidal stability also upon prolonged storage, one type 
of nanoparticles (IO-NP3) was prone to agglomera-
tion in serum-containing media, and was therefore 
excluded from biocompatibility testing. This under-
lines that only a careful nanoparticle analysis enables 
the design of a stable, clinically safe nanosystem.
The potential toxicity of nanoparticles is a major 
concern that must be excluded prior to their application 
in humans [39]. As nanoparticles may interfere with the 
available photometric methods for testing cell viability 
and/or metabolic activity [26,43–44], it is important to 
use in parallel at least two different methods for tox-
icity testing, to enable the verification of the results. 
In our studies, the biological effects of nanoparticles 
on endothelial cells were analysed in vitro using two 
real-time cell-monitoring methods. The obtained data 
underscore the importance of applying different meth-
ods to assess the toxicity of nanoparticles, as one single 
method may increase the risk of bias. For example, the 
impedance measurements indicated a negative effect of 
LD-NP1 at 100 μg/ml on HUVECs (cell-index sig-
nificantly lower in comparison to control), hinting to 
a reduced endothelial cell numbers, whereas the results 
of live-cell microscopy indicated a change in cell mor-
phology, possibly resulting in weaker adherence of the 
cells, that is responsible for the measured impedance 
differences. Smaller lipid nanoparticles (LD-NP1) 
had more pronounced effect on cell elongation and 
adherence of the cells than larger lipid nanoparticles. 
This could be due both to the effect of higher surfac-
tant concentration and the small size facilitating the 
uptake. Concerning the mechanisms of nanoparticle-
induced toxicity, we did not observe acute cell death 
accompanied by the rupture of plasma membrane, 
which would be indicative of necrosis. Based on the 
morphological features, including blebbing and cell 
shrinkage occurring over longer incubation periods, 
most probably the apoptotic processes were responsible 
for cell death induced at the concentrations of, and 
above, 100 μg/ml of the tested nanoparticles. To gain 
a more detailed insight into the mechanisms of toxic-
ity, future studies including annexin V and caspases 
staining would be necessary.
Compared with iron oxide nanoparticles, which 
have been extensively investigated for their effects on 
endothelial cells, very scarce information are avail-
able regarding the endothelial toxicity of solid lipid 
nanoparticles or polymeric nanoparticles composed of 
PIBCA. Lipid particles composed of cetyl palmitate 
and polysorbate 80 have been well tolerated by human 
cerebral microvascular endothelial cell line up to 1500 
μg/ml [6], although the selected exposure time was 
very short (4 h). Polymeric nanoparticles coated with 
fucoidan and dextran have previously been tested by 
Lira et al. [45] on macrophage and fibroblast cell lines, 
showing the IC
50
 of 9.6 μg/ml after 48 h incubation, 
but no data are available in the literature concerning 
their endothelial effects. Stealth liposomes of various 
compositions are generally well tolerated by endothe-
lial cells [46,47], which is in agreements with our pres-
ent observations. The largest pool of data related to 
endothelial toxicity is thus far available for iron oxide 
nanoparticles (reviewed in [48,49]). Based on the exist-
ing literature, the presence and the type of coating is a 
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Figure 6. See facing page. Biological effects of circulating PM-NPs and IO-NPs on endothelial cells grown under 
flow conditions. HUVECs were grown in bifurcating slides until confluence and perfused for 18 h with medium 
containing PM-NP1 (A), PM-NP2 (B), IO-NP1 (C), or IO-NP2 (D) at 100 and 400 μg/ml. Upper panel: Fluorescent 
images of representative laminar and nonuniform regions at 20× objective magnification are shown. F-actin 
was visualized with Alexa 488-conjugated 488 (green) and nucleus with Hoechst 33342 (blue). Lower panel: The 
graphs show a semiquantitative analysis of the confluence in laminar (green bars) and nonuniform region (red 
bars), determined on ×10 objective magnification images using ImageJ software. Nanoparticle-untreated controls 
(white columns) were set to 100%. Data are expressed as mean ± SEM.  
*p < 0.05, **p < 0.01, ***p < 0.001 vs corresponding control.
future science group
Nanoparticles for intravascular applications: physicochemical characterization & cytotoxicity testing    Research Article
decisive factor for the biocompatibility of these parti-
cles [50,51], with good endothelial compatibility of dex-
tran- and PEG-coated iron oxide nanoparticles up to 
500 μg/ml over 24 h, as reported by Yu et al. [50]. The 
net effect of iron oxide nanoparticles was also related to 
the amount of cellular uptake, which differs strongly 
among different formulations [51,52]. These data are 
in accordance with our observations, indicating very 
good biocompatibility of dextran-coated IO-NP2 at all 
tested concentrations, and little endothelial toxicity of 
lauric acid/albumin-coated IO-NP1 below 100 μg/ml.
It must be noted that the nanoparticle toxicity was 
tested up to a very high concentration (400 μg/ml). 
Such high doses (above 100 μg/ml) are not expected 
to occur in the systemic circulation in vivo, but may be 
encountered locally at the region of administration and 
should therefore be considered in analyses. Caution is 
also necessary when interpreting the results obtained 
with iron oxide nanoparticles versus other nanoparticle 
types, as the concentrations of the former are normal-
ized to the total iron content, which corresponds to a 
much higher total dry mass weight. We have applied 
long-term monitoring techniques instead of single-
point measurements, to ensure the toxicity readouts 
over extended time. Although some nanoparticles, 
particularly those intended for imaging applications 
will be expected to circulate for relatively short time, 
thus far no detailed pharmacokinetics and clearance 
data are available. Hence, the long-term effects must 
be investigated both for intended imaging and thera-
peutic nanosystems to ensure their safety also over 
extended periods of time.
In endothelial cells, constantly exposed to the blood 
flow, shear stress-activated mechanisms are one of the 
major modulators of the physiologic functions, but 
little is known about the influence of hemodynamic 
factors on the endothelial responses to circulating 
nanoparticles. In vitro assays in dynamic conditions 
corresponding to the physiological environment of 
endothelial cells are thus of critical importance, as 
the susceptibility to atherosclerosis is governed by the 
specific patterns of shear stress. In general, our data 
indicate that in case of nanoparticles, the cell culture 
assays under static conditions may overestimate the 
potential toxicity. This results from the inherent prop-
erty of nanoparticles, namely their sedimentation, 
which occurs over time and leads to increased effective 
concentrations of nanoparticles in the nearest vicinity 
of cell monolayer. As shown in our studies, this effect 
is responsible for the majority of the cytostatic and 
cytotoxic effects observed below the concentration of 
200 μg/ml. Only for one nanoparticle type (PM-NP2), 
the concentrations affecting cell growth and viability in 
static conditions (100 μg/ml) also induced cell detach-
ment under flow conditions, other nanosystems being 
well-tolerated under flow up to 400 μg/ml. This may 
be related to the fact that except IO-NP2, PM-NP2 are 
the only positively charged nanoparticles, characterized 
furthermore by a relatively large Z-average size and a 
tendency to aggregate. Collectively, these features may 
negatively affect endothelial cell growth and viability 
at concentrations of 100 μg/ml and higher. Moreover, 
the recently reported data as well as our present studies 
indicate that physiologic flow is one of the important 
factors that must be considered when designing drug 
delivery nanosystems, as the internalization of untar-
geted nanoparticles by endothelial cells differs greatly 
between static and dynamic conditions [34–36].
Due to their size, nanoparticles may remain in the 
circulation for several hours or more, and their in vivo 
behavior and interactions with cellular and extracellu-
lar substrates may induce undesired effects, including 
hemolytic reactions, and/or complement activation. 
Apart from clinical efficacy and safety, diagnostic and 
therapeutic nanosystems should therefore offer the pos-
sibility of repeated intravenous/intra-arterial adminis-
tration without inducing anaphylactoid (hypersensitiv-
ity) reactions. In this context, the clinical significance 
of CARPA-genic reaction upon the intravenous 
administration of nanosystems lies not only in the 
severe, occasionally lethal cardiopulmonary distress 
but also in a heightened risk that the nano medicines 
become immunogenic, preventing their multiple 
applications [32]. In order to minimize such risks, the 
nanoparticles included in our analyses are currently 
entering the CARPA tests in the pig model [53]. The 
results of a pilot study involving the intravenous bolus 
administration of LP-NP1 confirmed the in vitro data, 
indicating a favorable safety profile and low immuno-
genicity of these nanoparticles. In the next stage of the 
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Figure 7. Cardiovascular reaction to LP-NP1 in a pig model of CARPA. LP-NP1 (0.1 mg/kg or 0.5 mg/kg) were administered 
intravenously as a bolus injection. Saline and zymosan (0.1 mg/kg) were used as negative and positive controls, respectively. 
(A) Changes in SAP, HR and PAP upon iv. injection of NP-LP1. (B) Percentage changes in PAP after LP-NP1 injection. (C) Plasma 
concentrations of TXB2 in relation to PAP changes following LP-NP1 injection are shown.
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project, in vivo tests of other nanosystems selected for 
further development, as well as the determination of 
pharmacokinetics will be performed.
Conclusion
In this study we report the results of systematic physico-
chemical and biological analysis of diverse nanosystems 
intended for intravascular applications. The majority of 
nanosystems were well tolerated by endothelial cells, and 
did not induce major toxic effects in vitro up to the con-
centration of 100 μg/ml in static, and up to 400 μg/ml 
in dynamic cell culture conditions. These findings indi-
cate an overall favorable biocompatibility profile of the 
tested nanosystems and their potential for cardiovascular 
 imaging and drug targeting applications.
Future perspective
The potential clinical impact of nanotechnology in 
terms of detection and management of cardiovascu-
lar diseases is enormous. But in spite of the promising 
results obtained in the vast number of bench investiga-
tions that have been published in the recent years [4], no 
specific nanoparticle-based system has been approved 
for diagnosis or therapy of atherosclerosis in humans. 
The reasons for that are mainly the safety requirements 
related to nanoparticulate medicines, the lacking regu-
latory guidelines and insufficient standardization in the 
matters of particle characterization and nanotoxicity 
testing. To ensure clinical safety, the intravascular diag-
nostic and drug-delivery systems must first be subject to 
a close toxicologic scrutiny in vitro. Our studies represent 
an attempt to advance this field by utilizing a systematic 
approach to the comparative analysis of nanoparticle 
effects on primary human endothelial cells. Importantly, 
no interference resulting from the presence nanopar-
ticles was observed in real-time cell analysis method, 
indicating the suitability of this technique for the future 
nanotoxicology studies. Furthermore, the comparison 
of nanoparticle effects on cell viability in static culture 
conditions and the effects of circulating nanoparticles 
on endothelial monolayer under physiologic-like shear 
stress allowed the conclusion that the majority of tested 
nanosystems have very good biocompatibility profiles. 
To understand how the physicochemical features of 
nanoparticles can affect the specific cellular responses, 
we are currently investigating the functional effects of 
the described nanosystems in endothelial and mono-
cytic cells. These studies are expected to provide further 
important information concerning the mechanisms of 
nanoparticle-elicited cellular effects. Our pilot studies 
in the pig model confirmed the safety of liposomal for-
mulation (LP-NP1) in vivo, and constitute an important 
step toward further development and functionalization 
of these particles for the purpose of intravascular imag-
ing and targeted drug delivery. In the future, substantial 
amount of in vivo studies will be necessary before the 
nanosystems with proven in vitro safety and efficacy can 
be translated into clinical trials. But despite multiple 
safety and regulatory constraints, the future progress 
in diagnosis and treatment of cardiovascular disorders 
is expected to benefit strongly from the development of 
novel nanotechnology-based strategies.
It must also be noted that cardiovascular disease, 
including various clinical manifestations of atheroscle-
rosis and thrombosis, is but an example of the disease 
the therapy of which may profit from intravascular 
application of nanoparticulate drug carriers. In fact, 
the majority of the clinically-relevant nanocarriers, 
such as anticancer and anti-inflammatory nano-drugs, 
are expected to require intravascular administration. 
Although the main focus of our work is the diagnosis 
and therapy of atherosclerosis, the nanosystems inves-
tigated in this study constitute a versatile platform, 
adjustable also for the intravascular drug-delivery in 
other disease conditions.
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Executive summary
Background
•	 Detailed physicochemical and biological characterization of nanosystems in vitro is necessary to ensure their 
safety in more complex physiological conditions.
Methods
•	 We investigated 10 diverse nanosystems, comprising liposomes, lipid nanoparticles, polymeric and iron oxide 
nanoparticles to assess their long-term stability and biological effects on endothelial cells (ECs).
•	 EC viability in static conditions was monitored using real-time cell analysis and live-cell microscopy.
•	 A flow model of arterial bifurcations was used to assess the effect of circulating nanoparticles on EC 
monolayer under physiologic-like shear stress.
Results
•	 The majority of tested nanosystems were well tolerated by ECs up to the concentration of 100 μg/ml in static, 
and up to 400 μg/ml in dynamic conditions.
•	 In static conditions, nanoparticle sedimentation was responsible for the majority of the cytostatic and 
cytotoxic effects observed below nanoparticle concentration of 200 μg/ml.
•	 The results of a pilot study in a pig model showed that intravenous administration of liposomal nanoparticles 
did not evoke the hypersensitivity reaction, indicating a low immunogenicity of these nanoparticles.
Conclusion
•	 The majority of tested nanosystems had an overall favorable biocompatibility profile, constituting good 
candidates for cardiovascular imaging and drug targeting applications.
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